Sai Life Sciences IPO Details
The Sai Life Sciences IPO is a book build issue with a total issue size of ₹3042.62 cr, comprising of fresh issue of 17304189 equity shares., and a offer for sale of 38116934 equity shares. Sai Life Sciences IPO opened for subscription on Dec 11, 2024 and closed on Dec 13, 2024. Sai Life Sciences IPO is set price band at ₹522 to ₹549 per share, with a lot size of 27 shares. Minimum investment for Retail investors was ₹14,823.00 (at the upper price band) to apply for one lot.
The basis of allotment got finalized on Dec 16, 2024, and listed on both the NSE and BSE on Dec 18, 2024.
Kfin Technologies Limited has been appointed as the registrar. Morgan Stanley India Company Private Limited, Jefferies India Private Limited, Kotak Mahindra Capital Company Limited and IIFL Capital Services Limited are the Book Running Lead Manager for the issue.
Before investing in the Sai Life Sciences IPO, investors should review the company's financial performance, business objectives, and risk factors mentioned in the offer documents and apply before the subscription window closes.
- Price Band
- ₹ 522 – 549
- Lot Size
- 27
- Issue Size
- ₹3042.62 Cr
- Minimum Investment
- ₹14823 (27 Shares)
- Listing Date
- 18 December 2024
Current GMP
₹72 (+13.11%)
*Info is indicative. Not an Investment Advice. Grey market trading is unregulated.
About Sai Life Sciences Limited
Sai Life Sciences Limited is an innovator-focused contract research, development, and manufacturing organization (CRDMO) that provides end-to-end services across the drug discovery, development, and manufacturing value chain. It supports small molecule new chemical entities (NCEs) for global pharmaceutical and biotechnology firms. The company offers both contract research (CRO) and contract development and manufacturing (CDMO) capabilities.
Sai Life Sciences is one of the fastest-growing Indian CRDMOs in terms of revenue and EBITDA growth from FY 2022 to FY 2024. It serves over 280 pharmaceutical companies globally, including 18 of the top 25 pharmaceutical firms, with a significant presence in regulated markets like the US, UK, Europe, and Japan.
The company operates with research labs in innovation hubs like Greater Boston, US, and Manchester, UK, along with large-scale manufacturing facilities in India. This combination of global reach and cost-effective Indian operations allows Sai Life Sciences to support customers at various stages of the drug discovery-to-commercialization process.
Sai Life Sciences provides integrated CRO services in biology, chemistry, and drug metabolism, and has contributed to the approval of drugs and IND filings. In the CDMO space, it develops and manufactures active pharmaceutical ingredients (APIs) and intermediates for both clinical and commercial phases, including for blockbuster drugs.
The company has a diversified portfolio of over 170 innovator pharmaceutical products, including late-phase and early-phase drugs. It serves a broad customer base, with no single customer accounting for more than 8% of revenue. Its manufacturing facilities are accredited by global regulatory agencies, such as the USFDA and PMDA, Japan.
Sai Life Sciences is committed to sustainability, with initiatives aimed at energy conservation, increased use of renewable energy, and environmental protection. It has received a silver sustainability rating from EcoVadis and is a member of the Pharmaceutical Supply Chain Initiative (PSCI).
The company is led by an experienced management team, supported by investors like TPG Asia and HBM Private Equity India, and has a strong focus on corporate governance and environmental, social, and governance (ESG) strategies. As of September 2024, it employs over 3,100 staff, including a large team of scientists and engineers.
Sai Life Sciences IPO Promoters
- Kanumuri Ranga Raju
- Krishnam Raju Kanumuri
- Kanumuri Mytrey
- Sai Quest Syn Private Limited
- Sunflower Partners
- Lily Partners
- Marigold Partners
- Tulip Partners
Promoters Holding
Holding Pre Issue
40.48%
Holding Post Issue
35.10%
Sai Life Sciences IPO Objective
The company propose to utilise the Net Proceeds towards funding the following objects:
- Repayment/prepayment in full or part, of all or certain outstanding borrowings availed by the Company and
- General corporate purposes
Address / Contact Info
Sai Life Sciences Limited
Plot No. DS- 7, IKP Knowledge Park,
Turkapally Village, Shameerpet Mandal,
Medchal – Malkajgiri
District, Hyderabad 500 078,
Telangana
Phone: +9140 6815 6000
Email: investors@sailife.com
Website: https://www.sailife.com/
IPO Snapshot
Book Running Lead Managers
- Morgan Stanley India Company Private Limited
- Jefferies India Private Limited
- Kotak Mahindra Capital Company Limited
- IIFL Capital Services Limited
Disclaimer: This data is for informational purposes only and does not constitute investment advice. Figures shown are illustrative sample data.
Frequently Asked Questions
Everything you need to know before applying to an IPO.
Sai Life Sciences IPO is a Book-building IPO with a total issue size of ₹3042.62 crore. The Sai Life Sciences IPO price band is ₹522 to 549 per share. The Sai Life Sciences IPO subscription opens on Wed, Dec 11, 2024, and closes on Fri, Dec 13, 2024. The Sai Life Sciences IPO will be listed on the BSE,NSE. Kfin Technologies Limited is the registrar for the Sai Life Sciences IPO.
The Sai Life Sciences IPO opens on Wed, Dec 11, 2024 and closes on Fri, Dec 13, 2024
Sai Life Sciences IPO Price Band is ₹522 to 549 per share.
Sai Life Sciences IPO lot size is 27 shares, Retail investors need a minimum investment of ₹14823 based on the upper price band
The minimum investment for Sai Life Sciences IPO is ₹14823, based on one lot of 27 shares at the upper price band of ₹549 per share.
Investors can apply for the Sai Life Sciences IPO through the ASBA (Application Supported by Blocked Amount) facility offered by their bank or through UPI using a SEBI-registered broker or trading app. Select the desired lot size, enter your bid within the price band, and submit the application before Fri, Dec 13, 2024. The application amount remains blocked until the Sai Life Sciences IPO allotment is finalized.
Sai Life Sciences IPO issue size is ₹3042.62 crores.
Sai Life Sciences IPO allotment date is Wed, Jul 1, 2026.
The registrar for Sai Life Sciences IPO is Kfin Technologies Limited. Investors can go to Kfin Technologies Limited website to check Sai Life Sciences IPO allotment status, refund processing, and other IPO-related information.
The Sai Life Sciences IPO GMP (Grey Market Premium) is ₹72 as of Wed, Dec 18, 2024. Based on the upper price band of ₹549 per share, the estimated Sai Life Sciences IPO listing price is ₹621, indicating a potential listing gain of approximately 0% over the issue price.